Answers are grounded in this paper and cite their sources.
Case report demonstrates effective treatment of eyelid lupus using ruxolitinib, indicating potential for new therapies.
Lupus of the eyelids, or lupus blepharitis, is a rare and localized form of chronic cutaneous lupus. The use of topical corticosteroids is limited in this sensitive area due to the risk of adverse events. We present a case of eyelid lupus, with histological confirmation, resistant to multiple lines of treatment, successfully treated with ruxolitinib cream, with no relapse was observed after 1 year of follow‐up. This case illustrates the value of a topical JAK inhibitor for a localized form of cutaneous lupus that is refractory to conventional treatments, particularly in an area where standard therapies have limitations.
No takes yet. Share an insight, caveat, or question.
Bertold et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: